Analyses of short-term antagonistic evolution of Pseudomonas Aeruginosa strain PAO1 and phage KPP22 (Myoviridae family, PB1-like virus genus)

Applied and Environmental Microbiology

Volumn 82, Issue 15, 2016, Pages 4482-4491

  Uchiyama, Jumpei ^a   Suzuki, Masato ^b   Nishifuji, Koji ^c   Kato, Shin ichiro ^d   Miyata, Reina ^d   Nasukawa, Tadahiro ^a   Yamaguchi, Kotoe ^d   Takemura Uchiyama, Iyo ^a   Ujihara, Takako ^d   Shimakura, Hidekatsu ^a   Murakami, Hironobu ^a   Okamoto, Noriaki ^a   Sakaguchi, Yoshihiko ^e   Shibayama, Keigo ^b   Sakaguchi, Masahiro ^a   Matsuzaki, Shigenobu ^d  

^a AZABU UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^d KOCHI UNIVERSITY   (Japan)

^e KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA; CLONING; VIRUSES;

BACTERIAL RESISTANCE; IN-VITRO; OPEN READING FRAME; P.AERUGINOSA; PHAGE ADSORPTIONS; PHAGE THERAPY; PSEUDOMONAS AERUGINOSA; SHORT TERM;

BACTERIOPHAGES;

ADSORPTION; ANTAGONISM; BACTERIOPHAGE; BACTERIUM; BIOTECHNOLOGY; CLONE; EVOLUTIONARY BIOLOGY; INFECTIVITY; MUTATION;

ANIMALIA; BACTERIA (MICROORGANISMS); MYOVIRIDAE; PSEUDOMONAS AERUGINOSA;

ANTIBIOSIS; EVOLUTION; GENETICS; MYOVIRIDAE; PHYSIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PHAGE; VIROLOGY; VIRUS GENOME;

ANTIBIOSIS; BIOLOGICAL EVOLUTION; GENOME, VIRAL; MYOVIRIDAE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PHAGES;

EID: 84979895635     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.00090-16     Document Type: Article

References (51)

1. Lister P, Wolter D, Hanson N. 2009. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22:582-610. http:/dx.doi.org/10.1128/CMR.00040-09.
2. Breidenstein EB, de la Fuente-Núñez C, Hancock RE. 2011. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 19:419-426. http://dx.doi.org/10.1016/j.tim.2011.04.005.
3. Taylor PK, Yeung AT, Hancock RE. 2014. Antibiotic resistance in Pseudomonas aeruginosa biofilms: towards the development of novel antibiofilm therapies. J Biotechnol 191:121-130. http://dx.doi.org/10.1016/j.jbiotec.2014.09.003.
4. Matsuzaki S, Rashel M, Uchiyama J, Sakurai S, Ujihara T, Kuroda M, Ikeuchi M, Tani T, Fujieda M, Wakiguchi H, Imai S. 2005. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother 11:211-219. http://dx.doi.org/10.1007/s10156-005-0408-9.
5. Marza JA, Soothill JS, Boydell P, Collyns TA. 2006. Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients. Burns 32:644-646. http://dx.doi.org/10.1016/j.burns.2006.02.012.
6. Wright A, Hawkins CH, Anggård EE, Harper DR. 2009. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 34:349-357. http://dx.doi.org/10.1111/j.1749-4486.2009.01973.x.
7. Hawkins C, Harper D, Burch D, Anggård E, Soothill J. 2010. Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: a before/after clinical trial. Vet Microbiol 146:309-313. http://dx.doi.org/10.1016/j.vetmic.2010.05.014.
8. Rose T, Verbeken G, Vos DD, Merabishvili M, Vaneechoutte M, Lavigne R, Jennes S, Zizi M, Pirnay JP. 2014. Experimental phage therapy of burn wound infection: difficult first steps. Int J Burns Trauma 4:66-73.
9. Ceyssens PJ, Miroshnikov K, Mattheus W, Krylov V, Robben J, Noben JP, Vanderschraeghe S, Sykilinda N, Kropinski AM, Volckaert G, Mesyanzhinov V, Lavigne R. 2009. Comparative analysis of the widespread and conserved PB1-like viruses infecting Pseudomonas aeruginosa. Environ Microbiol 11:2874-2883. http://dx.doi.org/10.1111/j.1462-2920.2009.02030.x.
10. Ackermann H. 2011. Bacteriophage taxonomy. Microbiology Aust 32:90-94.
11. Pires DP, Vilas Boas D, Sillankorva S, Azeredo J. 2015. Phage therapy: a step forward in the treatment of Pseudomonas aeruginosa infections. J Virol 89:7449-7456. http://dx.doi.org/10.1128/JVI.00385-15.
12. Krylov V, Shaburova O, Krylov S, Pleteneva E. 2013. A genetic approach to the development of new therapeutic phages to fight Pseudomonas aeruginosa in wound infections. Viruses 5:15-53. http://dx.doi.org/10.3390/v5010015.
13. Krylov V, Pleteneva E, Shaburova O, Bourkaltseva M, Krylov S, Chesnokova E, Polygach O. 2014. Common preconditions for safe phage therapy of Pseudomonas aeruginosa infections. Adv Microbiol 4:766-773. http://dx.doi.org/10.4236/aim.2014.412084.
14. Fukuda K, Ishida W, Uchiyama J, Rashel M, Kato S, Morita T, Muraoka A, Sumi T, Matsuzaki S, Daibata M, Fukushima A. 2012. Pseudomonas aeruginosa keratitis in mice: effects of topical bacteriophage KPP12 administration. PLoS One 7:e47742. http://dx.doi.org/10.1371/journal.pone.0047742.
15. Labrie SJ, Samson JE, Moineau S. 2010. Bacteriophage resistance mechanisms. Nat Rev Microbiol 8:317-327. http://dx.doi.org/10.1038/nrmicro2315.
16. Scanlan PD, Buckling A, Hall AR. 2015. Experimental evolution and bacterial resistance: (co)evolutionary costs and trade-offs as opportunities in phage therapy research. Bacteriophage 5:e1050153. http://dx.doi.org/10.1080/21597081.2015.1050153.
17. Keen EC. 2012. Phage therapy: concept to cure. Front Microbiol 3:238. http://dx.doi.org/10.3389/fmicb.2012.00238.
18. Uchiyama J, Takemura I, Satoh M, Kato S, Ujihara T, Akechi K, Matsuzaki S, Daibata M. 2011. Improved adsorption of an Enterococcus faecalis bacteriophage EF24C with a spontaneous point mutation. PLoS One 6:e26648. http://dx.doi.org/10.1371/journal.pone.0026648.
19. Betts A, Vasse M, Kaltz O, Hochberg ME. 2013. Back to the future: evolving bacteriophages to increase their effectiveness against the pathogen Pseudomonas aeruginosa PAO1. Evol Appl 6:1054-1063. http://dx.doi.org/10.1111/eva.12085.
20. Friman VP, Soanes-Brown D, Sierocinski P, Molin S, Johansen HK, Merabishvili M, Pirnay JP, De Vos D, Buckling A. 2016. Pre-adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosa cystic fibrosis bacterial isolates. J Evol Biol 29:188-198. http://dx.doi.org/10.1111/jeb.12774.
21. Uchiyama J, Rashel M, Takemura I, Kato S, Ujihara T, Muraoka A, Matsuzaki S, Daibata M. 2012. Genetic characterization of Pseudomonas aeruginosa bacteriophage KPP10. Arch Virol 157:733-738. http://dx.doi.org/10.1007/s00705-011-1210-x.
22. Miyata R, Yamaguchi K, Uchiyama J, Shigehisa R, Takemura-Uchiyama I, Kato S, Ujihara T, Sakaguchi Y, Daibata M, Matsuzaki S. 2014. Characterization of a novel Pseudomonas aeruginosa bacteriophage, KPP25, of the family Podoviridae. Virus Res 189:43-46. http://dx.doi.org/10.1016/j.virusres.2014.04.019.
23. Ohtsubo Y, Ikeda-Ohtsubo W, Nagata Y, Tsuda M. 2008. Genome-Matcher: a graphical user interface for DNA sequence comparison. BMC Bioinformatics 9:376. http://dx.doi.org/10.1186/1471-2105-9-376.
24. Bertels F, Silander OK, Pachkov M, Rainey PB, van Nimwegen E. 2014. Automated reconstruction of whole-genome phylogenies from shortsequence reads. Mol Biol Evol 31:1077-1088. http://dx.doi.org/10.1093/molbev/msu088.
25. Shilov IV, Seymour SL, Patel AA, Loboda A, Tang WH, Keating SP, Hunter CL, Nuwaysir LM, Schaeffer DA. 2007. The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol Cell Proteomics 6:1638-1655. http://dx.doi.org/10.1074/mcp.T600050-MCP200.
26. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV. 2000. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406:959-964. http://dx.doi.org/10.1038/35023079.
27. Tsirigos KD, Peters C, Shu N, Käll L, Elofsson A. 2015. The TOPCONS web server for consensus prediction of membrane protein topology and signal peptides. Nucleic Acids Res 43:W401-W407. http://dx.doi.org/10.1093/nar/gkv485.
28. Davis MR, Goldberg JB. 2012. Purification and visualization of lipopolysaccharide from Gram-negative bacteria by hot aqueous-phenol extraction. J Vis Exp 63:e3916. http://dx.doi.org/10.3791/3916.
29. Islam ST, Huszczynski SM, Nugent T, Gold AC, Lam JS. 2013. Conserved-residue mutations in Wzy affect O-antigen polymerization and Wzz-mediated chain-length regulation in Pseudomonas aeruginosa PAO1. Sci Rep 3:3441. http://dx.doi.org/10.1038/srep03441.
30. Lam JS, MacDonald LA, Lam MY, Duchesne LG, Southam GG. 1987. Production and characterization of monoclonal antibodies against serotype strains of Pseudomonas aeruginosa. Infect Immun 55:1051-1057.
31. Homma JY. 1982. Designation of the thirteen O-group antigens of Pseudomonas aeruginosa; an amendment for the tentative proposal in 1976. Jpn J Exp Med 52:317-320.
32. Daniels L, Wais A. 1998. Virulence in phage populations infecting Halobacterium cutirubrum. FEMS Microbiol Ecol 25:129-134. http://dx.doi.org/10.1111/j.1574-6941.1998.tb00466.x.
33. Le S, He X, Tan Y, Huang G, Zhang L, Lux R, Shi W, Hu F. 2013. Mapping the tail fiber as the receptor binding protein responsible for differential host specificity of Pseudomonas aeruginosa bacteriophages PaP1 and JG004. PLoS One 8:e68562. http://dx.doi.org/10.1371/journal.pone.0068562.
34. Keen EC. 2014. Tradeoffs in bacteriophage life histories. Bacteriophage 4:e28365. http://dx.doi.org/10.4161/bact.28365.
35. Burrows LL, Charter DF, Lam JS. 1996. Molecular characterization of the Pseudomonas aeruginosa serotype O5 (PAO1) B-band lipopolysaccharide gene cluster. Mol Microbiol 22:481-495. http://dx.doi.org/10.1046/j.1365-2958.1996.1351503.x.
36. Knirel Y, Vinogradov EV, Kocharova NA, Paramonov NA, Kochetkov NK, Dmitriev BA, Stanislavsky ES, Lányi B. 1988. The structure of O-specific polysaccharides and serological classification of Pseudomonas aeruginosa (a review). Acta Microbiol Hung 35:3-24.
37. Islam ST, Lam JS. 2014. Synthesis of bacterial polysaccharides via the Wzx/Wzy-dependent pathway. Can J Microbiol 60:697-716. http://dx.doi.org/10.1139/cjm-2014-0595.
38. Lam JS, Taylor VL, Islam ST, Hao Y, Kocíncová D. 2011. Genetic and functional diversity of Pseudomonas aeruginosa lipopolysaccharide. Front Microbiol 2:118. http://dx.doi.org/10.3389/fmicb.2011.00118.
39. Heller K, Braun V. 1979. Accelerated adsorption of bacteriophage T5 to Escherichia coli F, resulting from reversible tail fiber-lipopolysaccharide binding. J Bacteriol 139:32-38.
40. Rakhuba DV, Kolomiets EI, Dey ES, Novik GI. 2010. Bacteriophage receptors, mechanisms of phage adsorption and penetration into host cell. Pol J Microbiol 59:145-155.
41. Henning U, Hashemolhosseini S. 1994. Receptor recognition by T-eventype coliphages, p 291-298. In Karam JD (ed), Molecular biology of bacteriophage T4. ASM Press, Washington, DC.
42. Chatterjee S, Rothenberg E. 2012. Interaction of bacteriophage with its E. coli receptor, LamB. Viruses 4:3162-3178. http://dx.doi.org/10.3390/v4113162.
43. Conley MP, Wood WB. 1975. Bacteriophage T4 whiskers: a rudimentary environment-sensing device. Proc Natl Acad Sci U S A 72:3701-3705. http://dx.doi.org/10.1073/pnas.72.9.3701.
44. Jarrell KF, Kropinski AM. 1981. Isolation and characterization of a bacteriophage specific for the lipopolysaccharide of rough derivatives of Pseudomonas aeruginosa strain PAO. J Virol 38:529-538.
45. Garbe J, Wesche A, Bunk B, Kazmierczak M, Selezska K, Rohde C, Sikorski J, Rohde M, Jahn D, Schobert M. 2010. Characterization of JG024, a Pseudomonas aeruginosa PB1-like broad host range phage under simulated infection conditions. BMC Microbiol 10:301. http://dx.doi.org/10.1186/1471-2180-10-301.
46. Chan BK, Abedon ST, Loc-Carrillo C. 2013. Phage cocktails and the future of phage therapy. Future Microbiol 8:769-783. http://dx.doi.org/10.2217/fmb.13.47.
47. Ormälä AM, Jalasvuori M. 2013. Phage therapy: should bacterial resistance to phages be a concern, even in the long run? Bacteriophage 3:e24219. http://dx.doi.org/10.4161/bact.24219.
48. León M, Bastías R. 2015. Virulence reduction in bacteriophage resistant bacteria. Front Microbiol 6:343. http://dx.doi.org/10.3389/fmicb.2015.00343.
49. Augustin DK, Song Y, Baek MS, Sawa Y, Singh G, Taylor B, Rubio-Mills A, Flanagan JL, Wiener-Kronish JP, Lynch SV. 2007. Presence or absence of lipopolysaccharideOantigens affects type III secretion by Pseudomonas aeruginosa. J Bacteriol 189:2203-2209. http://dx.doi.org/10.1128/JB.01839-06.
50. Hosseinidoust Z, Tufenkji N, van de Ven TG. 2013. Predation in homogeneous and heterogeneous phage environments affects virulence determinants of Pseudomonas aeruginosa. Appl Environ Microbiol 79:2862-2871. http://dx.doi.org/10.1128/AEM.03817-12.
51. Makin SA, Beveridge TJ. 1996. The influence of A-band and B-band lipopolysaccharide on the surface characteristics and adhesion of Pseudomonas aeruginosa to surfaces. Microbiology 142:299-307. http://dx.doi.org/10.1099/13500872-142-2-299.